Island Pharmaceuticals Limited (ILA.AX)
AUD 0.17
(-2.86%)
AUD 0.17
(-2.86%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -1.23 Million AUD | 38.03% |
| 2023 | -1.99 Million AUD | 58.26% |
| 2022 | -4.78 Million AUD | 25.9% |
| 2021 | -6.46 Million AUD | -646064300.0% |
| 2020 | -1.00 AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -1.23 Million AUD | -164.49% |
| 2024 Q2 | -468.21 Thousand AUD | 0.0% |
| 2024 Q1 | -468.21 Thousand AUD | 90.22% |
| 2024 Q4 | -1.23 Million AUD | 0.0% |
| 2024 FY | -1.23 Million AUD | 38.03% |
| 2023 Q2 | -3.32 Million AUD | 0.0% |
| 2023 Q1 | -3.32 Million AUD | 30.55% |
| 2023 Q3 | -1.99 Million AUD | 39.9% |
| 2023 Q4 | -4.78 Million AUD | -139.58% |
| 2023 FY | -1.99 Million AUD | 58.26% |
| 2022 Q2 | -5.82 Million AUD | 0.0% |
| 2022 Q1 | -5.82 Million AUD | 9.77% |
| 2022 FY | -4.78 Million AUD | 25.9% |
| 2022 Q4 | -4.78 Million AUD | 0.0% |
| 2022 Q3 | -4.78 Million AUD | 17.87% |
| 2021 Q1 | 1.00 AUD | 0.0% |
| 2021 FY | -6.46 Million AUD | -646064300.0% |
| 2021 Q4 | -6.46 Million AUD | 0.0% |
| 2021 Q3 | -6.46 Million AUD | 0.0% |
| 2020 FY | -1.00 AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -46.527% |
| Acrux Limited | -1.45 Million AUD | 15.061% |
| Actinogen Medical Limited | -9.13 Million AUD | 86.438% |
| AnteoTech Limited | -5 Million AUD | 75.239% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 92.217% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 90.26% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -26.097% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 90.077% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 32.09% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 76.762% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -74.532% |
| Biome Australia Limited | -1.56 Million AUD | 20.757% |
| Biotron Limited | -386.06 Thousand AUD | -220.775% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 98.438% |
| BTC Health Limited | -2.02 Million AUD | 38.758% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 59.436% |
| CSL Limited | 15.76 Billion AUD | 100.008% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 99.093% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 99.323% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 80.043% |
| Dimerix Limited | -21.99 Million AUD | 94.369% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 93.447% |
| Hexima Limited | -2.22 Million AUD | 44.372% |
| Immuron Limited | -11.48 Million AUD | 89.216% |
| Immutep Limited | -122.18 Million AUD | 98.986% |
| Imugene Limited | -91.56 Million AUD | 98.647% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 79.446% |
| Memphasys Limited | 4.13 Million AUD | 129.947% |
| Nanollose Limited | -96.22 Thousand AUD | -1186.993% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 92.755% |
| Noxopharm Limited | -2.31 Million AUD | 46.619% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 75.003% |
| Nyrada Inc. | -4.76 Million AUD | 74.034% |
| Orthocell Limited | -19.92 Million AUD | 93.785% |
| PharmAust Limited | -9.71 Million AUD | 87.251% |
| Patrys Limited | -2.24 Million AUD | 44.73% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 92.956% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 80.417% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 87.814% |
| PYC Therapeutics Limited | -65.76 Million AUD | 98.117% |
| Race Oncology Limited | -17.18 Million AUD | 92.795% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 93.333% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 63.535% |
| Starpharma Holdings Limited | -19.83 Million AUD | 93.756% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 98.829% |
| Tissue Repair Ltd | -16.44 Million AUD | 92.468% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 124.439% |